weiyuan wang

Dr. weiyuan wang

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
XZXiu-Fen Zhao
Xiu-Fen Zhao
WWweiyuan wang
weiyuan wang
XLXiaodong (Chris) Li
Xiaodong (Chris) Li
SLShu-Ping Li
Shu-Ping Li
FSFu-Gui Song
Fu-Gui Song

1 January 2022 in International Journal of Biological Sciences
Verified
Journal Article
Open access
Haihua WangHaihua Wang
Haihua Wang
WWweiyuan wang
weiyuan wang
SFSongqing Fan
Songqing Fan
Nasopharyngeal carcinoma (NPC) is a kind of malignant tumor with ethnic and geographical distribution characteristics. However, the molecular mechanisms of NPC are still unclear. Long non encoding RNAs (lncRNAs) are becoming important regulators in gene expression networks, including post transcriptional and post translational regulation of protein, protein complex organization, signal transduction and recombination among cells, which are involved in cancer recognition. Recent evidence shows that lncRNAs play important roles in the occurrence and development of NPC. Therefore, in-depth understanding of abnormal lncRNAs will provide new understanding of the pathogenesis in NPC, and provide new tools for the early diagnosis and treatment of NPC. This article reviews the abnormal lncRNAs in NPC cells and the roles of lncRNAs in the tumorigenesis of NPC. In addition, we also discuss the diagnostic and therapeutic potential of lncRNAs in NPC.

10 November 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
HWHai-Hua Wang
Hai-Hua Wang
SFSong-Qing Fan
Song-Qing Fan
YZYu-Ting Zhan
Yu-Ting Zhan
SPShu-Ping Peng
Shu-Ping Peng
WWweiyuan wang
weiyuan wang

18 March 2019 in Histopathology
Verified
Journal Article
Closed access
PDF file
JFJuan Feng
Juan Feng
GXGuiyuan Xie
Guiyuan Xie
YZYuting Zhan
Yuting Zhan
JLJunmi Lu
Junmi Lu
LXLina Xu
Lina Xu
WWweiyuan wang
weiyuan wang

8 March 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YZYuting Zhan
Yuting Zhan
XCXianyong Chen
Xianyong Chen
HZHongmei Zheng
Hongmei Zheng
JLJiadi Luo
Jiadi Luo
YYYang Yang
Yang Yang
SFSongqing Fan
Songqing Fan
Nasopharyngeal carcinoma (NPC) is the malignant tumor arising from the nasopharynx epithelium with ethnic and geographical distribution preference. Y-box binding protein-1 (YB1) is the highly expressed DNA/RNA-binding protein with cold shock domain, and enhanced YB1 expression was proved to be associated with many kinds of malignant tumors. There is no systematic study about the regulation of YB1 and cell proliferation, migration, invasion and stress granules (SGs) in NPC, and the relationship between YB1 expression and clinical characteristics and prognosis of NPC patients. We analyzed the mRNA expression of YBX1 in head and neck squamous carcinoma (HNSC) and NPC in databases, investigated the functions of YB1 in cell proliferation, migration and invasion and SGs formation of NPC cells, and detected expression of YB1 protein in a large scale of NPC samples and analyzed their association with clinicopathological features and prognostic significance of NPC patients. YBX1 mRNA was significantly high expression in HNSC and NPC by bioinformatic analysis, and higher expression of YBX1 mRNA indicated poorer prognosis of HNSC patients. Clinically, the expression of YB1 in NPC tissues was significantly higher than these in the control nasopharyngeal epithelial tissues. We further found that the expression of YB1 had an evidently positive relation with advanced clinical stages of patients with NPC. The overall survival rates (OS) were significantly lower for NPC patients with positive expression of YB1. Multivariate analysis confirmed that positive expression of YB1 was the independent poorer prognostic factor for patients with NPC. Moreover, compared with the immortalized nasopharyngeal epithelial cell line (NP69), the basal level of YB1 in NPC cell lines was significantly higher. Knocking down YB1 may inhibit Akt/mTOR pathway in NPC cells. Knocking down YB1 by small interfering RNAs can reduce the ability of proliferation, migration, invasion and SGs formation of NPC cells. The expression of YB1 in NPC cell lines or patients with NPC was significantly higher. The high expression of YB1 protein may act as one valuable independent biomarker to predict poor prognosis for patients with NPC. Knocking down YB1 may release the malignant phenotype of NPC cells.

16 January 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
HWHaihua Wang
Haihua Wang
SFSongqing Fan
Songqing Fan
YZYuting Zhan
Yuting Zhan
YXYue Xu
Yue Xu
YDYao Du
Yao Du
WWweiyuan wang
weiyuan wang
Approximately 80% of nasopharyngeal carcinoma (NPC) patients exhibit EGFR overexpression. The overexpression of EGFR has been linked to its potential role in modulating major histocompatibility complex class I (MHC-I) molecules. We discovered that EGFR, operating in a kinase-independent manner, played a role in stabilizing the expression of SLC7A11, which subsequently inhibited MHC-I antigen presentation. This mechanism, in turn, provided protection to NPC cells against T cell-mediated cytotoxicity. The underlying molecular processes revealed that the high and stable expression of SLC7A11 hindered the nuclear entry of GR, thereby suppressing TAP1 transcription and the presentation of MHC-I molecules. Additionally, elevated SLC7A11 expression led to an increase in FAF2 expression and triggered ERAD-dependent degradation of MHC-I, resulting in a reduction of MHC-I molecules on the cell membrane. The NPC patients exhibiting high EGFR and low MHC-I expression, combined with a scarcity of CD8+ T cells (EGFRhighMHC-IlowCD8few phenotype), experienced considerably shorter overall survival times compared to other situations. What is more, our study demonstrated that sorafenib had the capability to enhance the MHC-I antigen presentation process, thereby facilitating T cell-mediated killing of NPC cells via targeting SLC7A11. Consequently, targeting SLC7A11 with sorafenib emerges as a promising therapeutic strategy for the treatment of NPC.